Caging cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 4, 2015, Pages 867-869

  Balogh, Lajos P ^a  

^a AA Nanomedicine and Nanotechnology   (United States)

Author keywords

Cancer patients; Gd at C82(OH)22; Individual differences; Metallofullerenol; Treatment modalities; Tumoristatic

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FULLERENE DERIVATIVE; GADOLINIUM; GADOLINIUM FULLERENOL CAGE MOLECULE; GELATINASE A; GELATINASE B; HYDROXYL GROUP; OLIGONUCLEOTIDE; PACLITAXEL; UNCLASSIFIED DRUG; FULLERENOL;

ACUTE TOXICITY; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; BREAST EPITHELIUM CELL; CANCER CHEMOTHERAPY; CANCER STEM CELL; CAPILLARY DENSITY; CLINICAL PRACTICE; COWORKER; CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULE; NANODEVICE; NANOMEDICINE; NANOTECHNOLOGY; NOTE; PANCREAS CANCER; PH; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; SURFACE PROPERTY; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE; BREAST NEOPLASMS; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE; METABOLISM; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; FULLERENES; GADOLINIUM; HUMANS;

EID: 84929332506     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.02.005     Document Type: Note

References (28)

1. See e.g.,. http://www.abcam.com/tag/interactive/pathways.
2. See e.g., series of articles on the Tumor Microenvironment published in Nature Reviews Cancer.
3. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nat Rev Cancer 2012, 12:323-334.
4. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
5. Brucher B., Jamall I.S. Epistemology of the origin of cancer: a new paradigm. BMC Cancer 2014, 14:331-346.
6. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367(6464):645-648.
7. Korkaya H., Wicha M.S. Cancer stem cells: nature versus nurture. Nat Cell Biol 2010, 12:419-421.
8. Yasui W., Nishikawa S., Tahara E. Cancer stem cells. Cancer Sci 2007, 98(5):753-756.
9. 82 metallofullerene. Chem Phys Lett 1995, 232:273-277.
10. Mikawa M., Kato H., Okumura M., Narazaki M., Kanazawa Y., Miwa N., et al. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem 2001, 12:510-514.
11. 10 as a MRI contrast agent. J Am Chem Soc 2003, 125:5471-5478.
12. Xing G.M., Zhang J., Zhao Y.L., Tang J., Zhang B., Gao X.F., et al. Influences of structural properties on stability of fullerenols. J Phys Chem B 2004, 108(31):11473-11479.
13. Tang J., Xing G.M., Yuan H., Cao W.B., Jing L., Gao X.F., et al. Tuning electronic properties of metallic atom in bondage to a nanospace. J Phys Chem B 2005, 109(18):8779-8785.
14. Tang J., Xing G.M., Zhao Y.L., Jing L., Gao X.F., Cheng Y., et al. Periodical variation of electronic properties in polyhydroxylated metallofullerene materials. Adv Mater 2006, 18(11):1458-1462.
15. Tang J., Xing G.M., Zhao Y.L., Jing L., Yuan H., Zhao F., et al. Switchable semiconductive property of the polyhydroxylated metallofullerene. J Phys Chem B 2007, 111(41):11929-11934.
16. n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett 2005, 5(10):2050-2057.
17. Meng H., Xing G.M., Blanco E., Song Y., Zhao L.N., Sun B.Y., et al. Gadolinium metallofullerenol nanoparticles inhibit cancer metastasis through matrix metalloproteinase inhibition: imprisoning instead of poisoning cancer cells. Nanomed Nanotechnol Biol Med 2012, 8:136-146.
18. Song Y., Zhang M.Y., Zhao L.N., Yin X.H., Zhao J.H., Li J., et al. Regulation on mechanical properties of collagen: enhanced bioactivities of metallofullerol. Nanomed Nanotechnol Biol Med 2014, 10:783-793.
19. Liu Y., Chen C., Qian P., Lu X., Sun B., Zhang X., et al. Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell specific inhibitor. Nat Commun 2015, 6:5988.
20. Liang X.J., Meng H., Wang Y.Z., He H.Y., Meng J., Lu J., et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A 2010, 107(16):7449-7454.
21. 22 and its implication for de novo design of nanomedicine. Proc Natl Acad Sci U S A 2012, 109:15431-15436.
22. 22]n nanoparticles in tumor-bearing mice. Biochem Pharmacol 2006, 71(6):872-881.
23. Yin J.J., Lao F., Fu P.P., Wamer W.G., Zhao Y.L., Xing G.M., et al. Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger. Mol Pharmacol 2008, 74(4):1132-1140.
24. Lao F., Chen L., Li W., Ge C.C., Qu Y., Sun Q.M., et al. Fullerene nanoparticles selectively enter oxidation-damaged cerebral microvessel endothelial cells and inhibit JNK-related apoptosis. ACS Nano 2009, 3(11):3358-3368.
25. Meng H., Xing G.M., Sun B.Y., Zhao F., Lei H., Li W., et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano 2010, 4(5):2773-2783.
26. 22]n Nanoparticles induce dendritic cell maturation and activate Th1 immune responses. ACS Nano 2010, 4(2):1178-1186.
27. 22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity. Biomaterials 2009, 30(23-24):3934-3945.
28. Yin J.J., Lao F., Fu P.P., Wamer W.G., Zhao Y.L., Wang P.C., et al. The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials. Biomaterials 2009, 30(4):611-621.